We are live on ! Find out more
TELO icon

Telomir Pharmaceuticals
TELO

32 hedge funds and large institutions have $3.24M invested in Telomir Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 16 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.21% less ownership

Funds ownership: 9.43% → 7.22% (-2.2%)

8% less capital invested

Capital invested by funds: $3.51M → $3.24M (-$269K)

26% less funds holding

Funds holding: 43 → 32 (-11)

63% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 16

65% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 17

Holders
32
Holders Change
-11
Holders Change %
-25.58%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
6
Reduced
16
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Raymond James Financial
Raymond James Financial
Florida
+$111K
2
PWM
Praetorian Wealth Management
California
+$30.2K
3
Mariner
Mariner
Kansas
+$30.2K
4
UBS Group
UBS Group
Switzerland
+$22.3K
5
CA
Clearstead Advisors
Ohio
+$18.9K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$208K
2
BlackRock
BlackRock
New York
-$119K
3
Marshall Wace
Marshall Wace
United Kingdom
-$94.7K
4
YIH
Y-Intercept (HK)
Hong Kong
-$80.5K
5
Jane Street
Jane Street
New York
-$44.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$464 -$37.8K -25,073 -99%
Bank of America
27
Bank of America
North Carolina
$32 -$11.2K -7,420 -100%
AAP
28
Arax Advisory Partners
Colorado
$12 +$14 +9 New
SS
29
SBI Securities
Japan
$6 – – –
Barclays
30
Barclays
United Kingdom
$3 -$4.55K -3,015 -100%
Citigroup
31
Citigroup
New York
$1 -$3.13K -2,074 -100%
Marshall Wace
32
Marshall Wace
United Kingdom
– -$94.7K -75,770 Closed
YIH
33
Y-Intercept (HK)
Hong Kong
– -$80.5K -64,423 Closed
AQR Capital Management
34
AQR Capital Management
Connecticut
– -$41.5K -33,234 Closed
HF
35
HRT Financial
New York
– -$36K -28,889 Closed
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
– -$29.8K -23,817 Closed
TSS
37
Two Sigma Securities
New York
– -$28.6K -22,911 Closed
JG
38
Jain Global
New York
– -$20.5K -16,399 Closed
Squarepoint
39
Squarepoint
New York
– -$13.5K -10,829 Closed
TA
40
Tactive Advisors
Florida
– -$12.5K -10,000 Closed
Fidelity Investments
41
Fidelity Investments
Massachusetts
– -$7.01K -5,605 Closed
Carson Wealth (CWM LLC)
42
Carson Wealth (CWM LLC)
Nebraska
– -$4.08K -2,705 -100%
JP Morgan Chase
43
JP Morgan Chase
New York
– -$2.2K -1,762 Closed
FFO
44
Fortitude Family Office
Arizona
– -$834 -667 Closed
Wells Fargo
45
Wells Fargo
California
– -$186 -149 Closed
Nisa Investment Advisors
46
Nisa Investment Advisors
Missouri
– -$120 -96 Closed
EP
47
Essential Partners
California
– -$79 -63 Closed
AF
48
Allworth Financial
California
– -$15 -12 Closed
TWD
49
True Wealth Design
Ohio
– -$4 -3 Closed
1
2

TELO Hedge Fund Activity: Q3 2025 in Review

32 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Telomir Pharmaceuticals (TELO) for Q3 2025, worth a combined $3.24M — down 7.7% from $3.51M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of TELO and 6 opened new positions — a net loss of 11 holders — while 16 trimmed existing stakes and 6 added.

The largest buyer was Raymond James Financial, adding an estimated $111K. The largest seller was Goldman Sachs, cutting an estimated $208K.

  • 32 institutional investors held Telomir Pharmaceuticals (TELO) as of Q3 2025, down from 43 in Q2 2025.
  • Funds reported $3.24M of Telomir Pharmaceuticals stock for Q3 2025, down 7.7% quarter-over-quarter.
  • 6 funds opened new Telomir Pharmaceuticals positions in Q3 2025 and 17 closed out, a net change of -11 holders.
  • The largest Telomir Pharmaceuticals buyer in Q3 2025 was Raymond James Financial, an estimated $111K added.
  • The largest Telomir Pharmaceuticals seller in Q3 2025 was Goldman Sachs, an estimated $208K sold.

Based on aggregated 13F filings for Q3 2025.